Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole-brain Radioherapy in Brain Oligometastases: A Long-term Analysis
- MARIO BALDUCCI1,
- ROSA AUTORINO1⇑,
- SILVIA CHIESA1,
- GIANCARLO MATTIUCCI1,
- ANGELO POMPUCCI2,
- LUIGI AZARIO3,
- GIUSEPPE ROBERTO D'AGOSTINO1,
- MILENA FERRO1,
- ALBA FIORENTINO1,
- SERGIO FERSINO1,
- CIRO MAZZARELLA1,
- CESARE COLOSIMO4,
- VINCENZO FRASCINO1,
- CARMELO ANILE2 and
- VINCENZO VALENTINI1
- 1Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, Italy
- 2Department of Neurosurgery, Catholic University of the Sacred Heart, Rome, Italy
- 3Department of Physics, Catholic University of the Sacred Heart, Rome, Italy
- 4Department of Radiology, Catholic University of the Sacred Heart, Rome, Italy
- Correspondence to: Rosa Autorino, MD, Department of Radiation Oncology, Catholic University of the Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy. Tel: +39 0630155339, Fax: +39 0630155908, e-mail: rosa_autorino{at}yahoo.it
Abstract
Aim: To analyze the outcome of patients with brain oligometastases treated by radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) after whole-brain radiotherapy (WBRT). Patients and Methods: Overall survival (OS) and local control (LC) were evaluated in patients (patients) with 1-2 brain metastases. Results: Forty-seven patients were selected. They were submitted to WBRT (median dose=3,750 cGy) followed by SRS (17 patients; median dose=1,500 cGy) or FSRT (30 patients; median dose=2,000 cGy). Median follow-up was 102 months (range=17-151); the median survival was 22 months for the SRS group and 16 months for the FSRT group. One-year and 5-year survival was 56% and 16%, respectively, in SRT and 62.1% and 3%, respectively, in FSRT. Neither treatment proved to significantly impact OS (p=0.4). The 1-year LC rates were 80% and 61.1% in the two groups, respectively (p=0.15). Conclusion: SRS or FSRT after WBRT could offer the same outcomes in patients with brain oligometasteses. Further investigation is warranted to confirm these data and define the optimal stereotactic modality.
- Received February 5, 2015.
- Revision received February 19, 2015.
- Accepted February 22, 2015.
- Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
